Dr. Besse Discusses MARIPOSA Analysis on Mechanisms of Acquired Resistance

Benjamin Besse, MD, PhD, of Gustave Roussy, discusses an analysis from the phase 3 MARIPOSA study that evaluated mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).

Dr. Besse presented the data during a late-breaking abstract at the European Society of Medical Oncology (ESMO) Congress 2024.

“The resistance mechanisms to this combination were unknown and are presented for the first time at this ESMO 2024,” Dr. Besse said. “It’s important to understand that among all the patients that were randomized in the two arms, only a portion of these patients had disease progression. In these patients, we matched a baseline liquid biopsy to a liquid biopsy at the time of resistance.”

Dr. Besse explained the implications of the results from the next-generation sequencing analysis of circulating tumor DNA from patients receiving first-line amivantamab plus lazertinib versus osimertinib.

“The combination treatment decreased by threefold and eightfold the resistance pathway on MET and EGFR compared to osimertinib alone…” Dr. Besse concluded. “Altogether, this data show that amivantamab and lazertinib have a potent inhibition and decrease the rate of resistance mechanism both on MET and EGFR.”